newsfilter
← Latest News
Business Wire·

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

  • Contineum Therapeutics (NASDAQ: CTNM) announced two scientific posters for its lead candidate PIPE-791 at the ATS 2026 International Conference in Orlando, Fla., scheduled for May 15-20, 2026.
  • The first poster, titled "PIPE-791 & BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists With Distinct Lung Occupancy Profiles & Vascular Effects," is presented by Chief Scientific Officer Daniel S. Lorrain, Ph.D., as Poster P155 on Monday, May 18, 2026.
  • The second poster, titled "LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro," is presented by VP of Biology Michael Poon, Ph.D., as Poster P156 on Monday, May 18, 2026.
  • Both presentations occur from 11:30 a.m. to 1:15 p.m. ET during the "From Target Discovery to Clinical Translation in Pulmonary Fibrosis" session.
  • PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis & chronic pain.
  • Contineum is also advancing PIPE-307, a selective M1 receptor inhibitor, for relapsing-remitting multiple sclerosis & major depressive disorder.
  • Abstracts are accessible to registered users on the ATS 2026 itinerary planner & on the company's website Publications page.